RT期刊文章SR电子T1 FTLD光谱的表征通过先进diffusion-weighted MRI指标:连接体的方法(赛0 - 6.003)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP 4015 10.1212 / WNL。首页0000000000203682签证官100 17补充2 A1 Federica Agosta A1西尔维亚Basaia A1 Federica Facente A1卡米拉Cividini A1 Edoardo卢卡雷利A1 Elisa Canu A1 Veronica Castelnovo A1朱塞佩•马格纳尼A1弗朗西斯卡卡索A1 Paola Caroppo A1莎拉Prioni A1克里斯蒂娜别墅A1卢西奥Tremolizzo A1 Ildebrando Appollonio A1 Vincenzo Silani A1马西莫菲利皮主持年2023 UL //www.ez-admanager.com/content/100/17_Supplement_2/4015.abstract AB目的:探讨结构性改变大脑网络的患者在额首页颞叶的变性(FTLD)频谱使用的连接体分析先进diffusion-weighted MRI指标。背景:核磁共振——是一个有前途的工具来描述基于网络的退化在神经退行性疾病。神经突方向色散和密度成像(NODDI)显示在结构连通性变化提供新的见解。设计/方法:34 behavioral-variant额颞叶痴呆(bvFTD), 11个语义变体原发性进行性失语(svPPA), 11迟滞型(nfvPPA)患者和48名健康对照组接受multi-shell扩散磁共振成像。计算分数各向异性(FA)地图。胞内体积分数(ICVF)地图也使用NODDI估计,提供一个直接量化神经突的完整性。图分析和评估——全球和本地拓扑网络结构属性和地区结构连接。结果:总体而言,普遍存在的结构性变化观察bvFTD患者相对于健康对照组和svPPA病人FA-derived网络属性。nfvPPA病人还显示改变FA拓扑性质在全球水平与健康对照组相比。节点权重的总和(SN)感觉运动叶透露,nfvPPA病人比svPPA显示连接强度的改变。 Moreover, nfvPPA patients showed a significant decreased FA in the left hemispheric fronto-temporal-insular regions relative to controls. Considering ICVF, more severe alterations compared to FA maps allowed to find differences also between svPPA and nfvPPA patients. ICVF graph analysis measures also showed that svPPA had a lower degree centrality and SN in the temporal lobe compared to controls.Conclusions: These findings suggest that conventional diffusion-tensor measures might be sensitive enough to highlight vulnerable connections in the FTLD spectrum. However, ICVF demonstrated to be a more specific biomarker to differentiate FTLD syndromes. Specifically, the benefits emerged in the differentiation between svPPA patients and other groups.Disclosure: Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC. Silvia Basaia has nothing to disclose. Dr. Facente has nothing to disclose. Ms. Cividini has nothing to disclose. Dr. Spinelli has nothing to disclose. The institution of Elisa Canu has received research support from Italian Ministry of Health . Dr. Castelnovo has nothing to disclose. Giuseppe Magnani has nothing to disclose. Dr. Caso has nothing to disclose. Paola Caroppo has nothing to disclose. Sara Prioni has nothing to disclose. Miss Villa has nothing to disclose. Lucio Tremolizzo has nothing to disclose. Dr. Appollonio has nothing to disclose. Dr. Silani has nothing to disclose. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).